Join the club for FREE to access the whole archive and other member benefits.

Chroma Medicine

Epigenetic editing company, therapy based on epigenetics

Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, revolutionizing the treatment of genetically driven diseases.

The epigenome is nature’s gatekeeper for gene expression, governing cell phenotype and function by precisely controlling gene activity without changing the underlying DNA sequence. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma Medicine is working at the cutting edge of precision genomics, building an entirely new class of therapeutics to achieve unparalleled control of gene expression.

Visit website: https://chromamedicine.com/

 people

 chromamedicine

Details last updated 01-Jul-2022

Mentioned in this Resource

Jonathan Weissman

Professor at University of California San Francisco and Investigator at Howard Hughes Medical Institute

Other people at Chroma Medicine

Catherine Stehman-Breen

Chief Executive Officer at Chroma Medicine

Chroma Medicine News

Chroma secures new investment of 135M for Series B in genetic medicines

Chroma secures new investment of 135M for Series B in genetic medicines

Biospace - 01-Mar-2023

Epigenetic medicine approach avoids the pitfalls of traditional CRISPR method of gene editing

Epigenome editing - technology  safer and reversible than CRISPR

Epigenome editing - technology safer and reversible than CRISPR

Science - 01-Jun-2022

Leaves DNA sequence unaltered while retaining the ability to specifically home